Connect with us

Health

9 Meters Biopharma (NMTR) Announces Publication in Journal of Clinical Investigation Describing Successful Use of Larazotide for Treating Multisystem Inflammatory Syndrome in Children (MIS-C) resultin – StreetInsider.com

9 Meters Biopharma, Inc. (NASDAQ: NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced the publication of an article…

Published

on

Article feature image
ADVERTISEMENT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premiumhere.
9 Meters Biopharma, Inc. (NASDAQ: NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced the publication of an article in the Journal of Clinical Investigation demonstrating the use of larazotide in successfully treating a 17-month infant with multisystem inflammatory syndrome in children (MIS-C). Larazotide is a novel first-in-class tight junction…

Click here to view the original article.

Continue Reading
Advertisement
Advertisement

Trending